Please login to the form below

Not currently logged in
Email:
Password:

Pfizer to close UK manufacturing site

Pfizer says that over 400 jobs will be lost when it closes its remaining manufacturing operations in Sandwich, UK

US-based pharmaceutical company Pfizer has revealed that over 400 jobs will be lost when it closes its remaining manufacturing operations in Sandwich, UK.

Pfizer confirmed the decision to close the Sandwich plant on 11 September in a press statement, but stressed that the closure was part of its previously announced plans to consolidate its worldwide manufacturing operations to manage global capacity and demand more efficiently.

Pfizer, which employs approximately 90,000 people globally, said earlier in 2007 that it needed to shed more than 10,000 jobs to make cost savings after disappointing FY06 results.

Pfizer's vice-president of manufacturing, Tony Maddaluna, said: "It is with regret that we announce our decision to end manufacturing operations in Sandwich after 53 years. This is the latest in a number of global manufacturing changes to ensure we are operating as efficiently and effectively as possible and able to respond to the challenges of today's business environment."

Pfizer added that it would support staff affected by the decision by redeploying them if possible and insisted that the Sandwich site would continue to serve as one of its four key R&D sites across the globe.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics